Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

softesule pvt. ltd. de india - alfacalcidol - alfacalcidol....1.0 mcg

United States - English - NLM (National Library of Medicine)

jurox pty. limited - alfaxalone (unii: bd07m97b2a) (alfaxalone - unii:bd07m97b2a) - alfaxan multidose idx is indicated as a sedative and anesthetic in multiple minor species*. more specifically, alfaxan multidose idx is indicated for the following: - for sedation and anesthesia in captive reptiles, excluding any food‑producing species** - for sedation and anesthesia in captive amphibians, excluding any food‑producing species** - for sedation and anesthesia in ornamental fish, including species used in research such as the zebrafish - for sedation and anesthesia in captive species and pet birds in the orders psittaciformes, passeriformes, and columbiformes, excluding any food‑producing species** - for sedation and anesthesia in non‑human primates - for sedation and anesthesia in captive rodents - for sedation and anesthesia in captive mustelids - for sedation and anesthesia in captive marsupials - for induction of anesthesia and immobilization in captive minor species ungulates, excluding any food‑producing species** use only when there is reasonable certainty that the treated animal will not be consumed by humans or food‑producing animals. *    the term “minor species” means animals other than humans that are not major species. “major species” means cattle, horses, swine, chickens, turkeys, dogs and cats. ** as used on this label, a “food‑producing minor species” is considered to be a minor species of which some members are bred, cultured, farmed, ranched, hunted, caught, trapped or otherwise harvested for the purpose of having the animals or edible products of the animals commercially distributed for consumption by humans or food‑producing animals in the united states. alfaxan multidose idx is contraindicated in animals with a known sensitivity to alfaxan multidose idx or its components, or when general anesthesia and/or sedation are contraindicated. do not use in any minor species animal that may become eligible for consumption by humans or food‑producing animals. controlled substance : alfaxan multidose idx contains alfaxalone a neurosteroid anesthetic and a class iv controlled substance. abuse : alfaxalone is a central nervous system depressant that acts on gaba receptor associated chloride channels, similar to the mechanism of action of schedule iv sedatives such as benzodiazepines (diazepam and midazolam), barbiturates (phenobarbital and methohexital) and fospropofol. in a drug discrimination behavioral test in rats, the effects of alfaxalone were recognized as similar to those of midazolam. these biochemical and behavioral data suggest that alfaxalone has an abuse potential similar to other schedule iv sedatives. physical dependence : there are no data that assess the ability of alfaxalone to induce physical dependence. however, alfaxalone has a mechanism of action similar to the benzodiazepines and can block the behavioral responses associated with precipitated benzodiazepine withdrawal. therefore, it is likely that alfaxalone can also produce physical dependence and withdrawal signs similar to that produced by the benzodiazepines. psychological dependence : the ability of alfaxalone to produce psychological dependence is unknown because there are no data on the rewarding properties of the drug from animal self-administration studies or from human abuse potential studies.

United States - English - NLM (National Library of Medicine)

par pharmaceutical inc. - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate oral  suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer. sucralfate oral  suspension is contraindicated for patients with known hypersensitivity reactions to the active substance or to any of the excipients.

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate tablets, usp are indicated in: - short-term treatment (up to 8 weeks) of active duodenal ulcer. while healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. sucralfate tablets are contraindicated in patients with known hypersensitivity reactions to the active substance or to any of the excipients.

United States - English - NLM (National Library of Medicine)

atlantic biologicals corp. - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate oral suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer. sucralfate oral suspension is contraindicated for patients with known hypersensitivity reactions to the active substance or to any of the excipients.

United States - English - NLM (National Library of Medicine)

denton pharma, inc. dba northwind pharmaceuticals - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate is indicated in: - short-term treatment (up to 8 weeks) of active duodenal ulcer. while healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. sucralfate is contraindicated in patients with known hypersensitivity reactions to the active substance or to any of the excipients.

United States - English - NLM (National Library of Medicine)

avpak - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate oral suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer. sucralfate oral suspension is contraindicated for patients with known hypersensitivity reactions to the active substance or to any of the excipients.

United States - English - NLM (National Library of Medicine)

denton pharma, inc. dba northwind pharmaceuticals - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate is indicated in: - short-term treatment (up to 8 weeks) of active duodenal ulcer. while healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. sucralfate is contraindicated in patients with known hypersensitivity reactions to the active substance or to any of the excipients.

United States - English - NLM (National Library of Medicine)

natco pharma usa llc - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate oral suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer. sucralfate oral suspension is contraindicated for patients with known hypersensitivity reactions to the active substance or to any of the excipients.

United States - English - NLM (National Library of Medicine)

pinnacle pharma llc - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate oralsuspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer. sucralfate oralsuspension is contraindicated for patients with known hypersensitivity reactions to the active substance or to any of the excipients.